Managing atypical antipsychotic-associated weight gain: 12-Month data on a multimodal weight control program

Journal of Clinical Psychiatry

Volumn 65, Issue 4, 2004, Pages 471-477

  Menza, Matthew ^a,b,c   Vreeland, Betty ^a,b   Minsky, Shula ^a,b   Gara, Michael ^a,b   Radler, Diane Rigassio ^b   Sakowitz, Marie ^b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BEHAVIOR THERAPY; BLOOD PRESSURE; BODY MASS; CHEMICALLY INDUCED DISORDER; COUNSELING; DRUG EFFECT; EXERCISE; GROUP THERAPY; HEALTH BEHAVIOR; HUMAN; MOTIVATION; MULTIMODALITY CANCER THERAPY; OBESITY; PATIENT COMPLIANCE; PHYSIOLOGY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; BLOOD PRESSURE; BODY MASS INDEX; COMBINED MODALITY THERAPY; COUNSELING; EXERCISE; HEALTH BEHAVIOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MOTIVATION; OBESITY; PATIENT COMPLIANCE; PSYCHOTHERAPY, GROUP; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT LOSS;

EID: 2442509789     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0404     Document Type: Article

References (39)

1. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002;55:277-284
2. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220 (Pubitemid 29193917)
3. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-912 (Pubitemid 30809169)
4. Sernyak M, Leslie D, Alarcon R, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566 (Pubitemid 34274937)
5. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatry 2001;179:498-502 (Pubitemid 34031673)
6. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 2000;321:483-484
7. Jeste DV, Gladsjo JA, Lindamer LA, et al. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22:413-430 (Pubitemid 26295345)
8. Vieweg V, Levenson J, Pandurangi A, et al. Medical disorders in the schizophrenic patient. Int J Psychiatry Med 1995;25:137-172
9. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128 (Pubitemid 36084056)
10. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(suppl 7):32-37 (Pubitemid 32402183)
11. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701 (Pubitemid 29261358)
12. Allison DB, Mentore JL, Moonseong H, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696 (Pubitemid 29517559)
13. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999;60(suppl 21):20-24 (Pubitemid 29523629)
14. Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999;60(suppl 21):16-19 (Pubitemid 29523628)
15. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 2001;11(suppl 4):S391-S396 (Pubitemid 32928374)
16. Nasrallah HA, Mulvihill T. Iatrogenic disorders associated with conventional vs atypical antipsychotics. Ann Clin Psychiatry 2001;13:215-227 (Pubitemid 34273561)
17. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22 (Pubitemid 34438915)
18. Ridgeway NA, Harvill DR, Harvill LM, et al. Improved control of type 2 diabetes mellitus: a practical education/behavior modification program in a primary care clinic. South Med J 1999;92:667-672 (Pubitemid 29334683)
19. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-1586 (Pubitemid 32681139)
20. National Heart, Lung, and Blood Institute (NHLBI). Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md: National Heart, Lung, and Blood Institute; 1998
21. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21 (Pubitemid 32193047)
22. Eckman TA, Wirshing WC, Marder SR, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 1992;149:1549-1555
23. Mueser KT, Corrigan PW, Hilton DW, et al. Illness management and recovery: a review of the research. Psychiatr Serv 2002;53:1272-1284
24. Aquila R, Emanuel M. Interventions for weight gain in adults treated with novel antipsychotics. Primary Care Companion J Clin Psychiatry 2000;2:20-23
25. Knox JM. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980;136:287-289 (Pubitemid 10081829)
26. Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self control program. Psychol Rep 1980;46:483-486
27. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363 (Pubitemid 29289721)
28. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001:52:967-969 (Pubitemid 32634719)
29. Littrell KH, Petty RG, Hilligoss NM, et al. Educational interventions for the management of antipsychotic-induced weight gain [poster]. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
30. Prochaska J, DiClemente C, Norcross J. In search of how people change: applications to addictive behaviors. Am Psychol 1992;47:1102-1114
31. Littrell KH, Ryan SW, Sowers C, et al. Solutions for Wellness. Indianapolis, Ind: Eli Lilly and Company; 2000
32. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behaviors. New York, NY: The Guilford Press; 1991
33. Vreeland B, Menza M, Gara M, et al. Healthy Living: an approach to weigh loss in schizophrenic patients taking atypical antipsychotics. Psychiatr Serv. In press
34. Fontaine KR, Moonseong H, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rates. Psychiatry Res 2001;101:277-288 (Pubitemid 32324233)
35. Institute of Medicine. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: National Academy Press; 1995
36. Green AI, Patel JK, Goisman RM, et al. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224-235 (Pubitemid 30629004)
37. National Heart Lung and Blood Institute (NHLBI). The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). NIH publication 98-4080. Bethesda, Md: National Heart, Lung, and Blood Institute; 1997
38. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286:1195-1200 (Pubitemid 33015548)
39. Kaplan LM. Weigh Less, Live Longer: Strategies for Successful Weight Loss: A Special Health Report From Harvard Medical School. Boston, Mass: Harvard Health Publications; 2001